SCHEMBL171912

SCHEMBL171912

Clc1cc(Br)ccn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29800398 1.00
SCHEMBL1275114 0.87 LOXL2 (0.38)
SCHEMBL16232294 0.81 IDO1 (0.50)
SCHEMBL14154863 0.77 BIRC5 (0.45)
SCHEMBL9045874 0.72 EGFR (0.52)
SCHEMBL4736199 0.72 FFAR1 (0.44)
SCHEMBL30961281 0.72 SMN1; SMN2 (0.37)
SCHEMBL4027001 0.72 IDO1 (0.55)
SCHEMBL4614 0.72
SCHEMBL833371 0.72 KDM4E (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1015 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118852114-A Light affinity probe for targeting cyclin-dependent kinase 9 and preparation method and application thereof 南京科络思生物科技有限公司 2024-10-29 CN claimed
CN-117756711-A Synthesis method of 4-bromo-2-chloro-6-hydroxymethylpyridine 凯美克(上海)医药科技有限公司 2024-03-26 CN claimed
CN-105294546-B A kind of pyridine compounds and preparation method thereof 天津市斯芬克司药物研发有限公司 2017-12-08 CN claimed
CN-105294546-A Pyridine compound and preparation method thereof TIANJIN SPHINX MEDICINE RES AND DEV CO LTD 2016-02-03 CN claimed
CN-122055363-A Compounds and methods for modulating splicing 雷密克斯医疗公司 2026-05-15 CN disclosed
EP-3856736-B1 NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2026-05-06 EP disclosed
WO-2026090477-A1 HELICASE INHIBITORS AND USES THEREOF KIMIA THERAPEUTICS, INC. (US) 2026-04-30 WO disclosed
EP-4727921-A1 DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF Deciphera Pharmaceuticals, LLC (US) 2026-04-22 EP disclosed
EP-4727922-A1 DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF Deciphera Pharmaceuticals, LLC (US) 2026-04-22 EP disclosed
EP-4727920-A1 DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF Deciphera Pharmaceuticals, LLC (US) 2026-04-22 EP disclosed
US-20260103464-A1 CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2026-04-16 US disclosed
EP-4724438-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING Remix Therapeutics Inc. (US) 2026-04-15 EP disclosed
WO-2006094639-A1 PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2006-09-14 WO disclosed
US-20060199960-A1 e.g. 6-Methyl-3-(pyridin-3-ylamino)-pyridine-2-carboxylic acid (4-methyl-thiazol-2-yl)-amide; metabotropic glutamate receptor antagonists (mGluR); central nervous system disorders, antidepressant, anxiolytc agent; psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders HOFFMANN-LA ROCHE INC. 2006-09-07 US disclosed
EP-1659112-A1 Arylpiperazuine derivatives as selective ligand for the dopamine D3 receptor BIOPROJET (FR) 2006-05-24 EP disclosed
US-20060089364-A1 Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents BIOPROJET (FR) 2006-04-27 US disclosed
US-20060089364-A1 Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents BIOPROJET (FR) 2006-04-27 US disclosed
US-20060089364-A1 Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents BIOPROJET (FR) 2006-04-27 US disclosed
WO-2006032631-A1 INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 JANSSEN PHARMACEUTICA N.V. (BE) 2006-03-30 WO disclosed
CN-1255042-A Diaryl ethers and processes for their preparation and herbicidal and desiccant compositions containing them ISK AMERICAS INC (US) 2000-05-31 CN disclosed